The Women's Cancer Developmental Therapeutics Program (WCDTP) seeks to increase the development of novel cancer therapies in Gynecologic and Breast cancers, leading to a decrease in cancer-related morbidity and mortality for patients. Additionally, the WCTD seeks to increase access to Phase I/II clinical trials of novel cancer therapies for patients with Gynecologic and Breast cancers.

​Women's Cancers include: 

Breast, Endometrial, Ovarian, Fallopian tube, Peritoneal, Cervical, Vulvar, and Vaginal. 

• It is estimated that there will be approximately 268,600 women newly diagnosed with breast cancer and 109,000 women newly diagnosed with gynecologic cancer and approximately 41,760 deaths from breast cancer and 33,100 deaths from gynecologic cancers in the United States during 2019 (American Cancer Society. Cancer Facts & Figures 2019). 
• Only about 5% of women with gynecologic cancer participate in dozens of clinical trials in gynecologic cancers. (foundationsforwomenscancer). 
• According to the Cancer Therapy Evaluation Program within NCI, approximately 3% of adult cancer patients participate in clinical trials. 

WCDTP Mission: 

To increase the development of novel cancer therapies in Gynecologic and Breast cancers, leading to a decrease in cancer-related morbidity and mortality for patients. Increase access to Phase I/II clinical trials of novel cancer therapies for patients with Gynecologic and Breast cancers.

Current available trials

Gynecologic cancer clinical trials - July 1, 2020

Breast cancer clinical trials - July 1, 2020